Contraline
Charlottesville, US · Founded 2017 · Delaware corporation · 29 employees on LinkedIn · 21 known investors
Find your way into Contraline
111 people in our graph share verified history with the Contraline team — schools, employers, funds. One of them is your warm intro.
Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception. The company works on translational reproductive biology research to bring new contraceptive options to market.
Also known as Contraline, Inc.
Founders & leadership
Contraline was founded in 2017 by Kevin Eisenfrats and John Herr.
Board
Investors · 21
Funding
SEC filings, press & company announcements$155.5M disclosed across 3 of 5 rounds · 2021–2026
- $92.5MSeries BJun 2026Source ↗
▶$55.8MraisedJun 2026 · 77 investors · BiotechnologyRule 506(b)
- Kevin S EisenfratsExecutive Officer, Director, Promoter
- Iris Van Alderwerelt van RosenburghDirector
- Martin J EmersonDirector
- Gurdane BhutaniDirector
- Offering amount
- $115.9M
- Amount sold
- $55.8M
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.2MraisedApr 2022 · 22 investors · BiotechnologyRule 506(b)
- Martin EmersonDirector
- Gurdane BhutaniDirector
- Tom ThorpeDirector
- Michael KingDirector
- Kevin EisenfratsExecutive Officer, Director, Promoter
- Offering amount
- $7.5M
- Amount sold
- $7.2M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Contraline is a Charlottesville, Virginia-based company developing contraceptive options for men and couples. Its stated aim is to create contraceptives that are effective, safe and reversible, and it positions its work as the first significant addition to male contraceptive methods since the vasectomy.
The pipeline comprises two investigational programs. ADAM is an implant designed to deliver long-lasting, non-hormonal and reversible contraception. NES/T is an investigational drug administered as a daily topical gel intended to pause sperm production. The company also operates a clinical trial participation channel for prospective study subjects. Contraline states that its products are investigational and have not been approved by the U.S. Food and Drug Administration or any other regulatory authority.
Traction
The company's public timeline states that two of its investigational male contraceptives completed clinical trials in 2025, and it announced a $92.5 million Series B financing to advance its male contraception work.
Latest developments
Contraline announced a $92.5 million Series B round to advance its male contraception programs, and reports that two of its investigational contraceptives completed clinical trials in 2025.
▸Full profile — market position, technology, go-to-market, geography, risks & controversies
Market position
Contraline describes its work as addressing a gap in contraceptive innovation, noting that male methods have not materially expanded since the vasectomy and that prior approved methods (condoms, the birth control pill, IUDs, female condoms, emergency contraception) largely target women.
Technology
Contraline's two disclosed programs are ADAM, an implant intended to provide long-lasting, non-hormonal and reversible contraception, and NES/T, an investigational drug delivered as a daily topical gel designed to pause sperm production.
Go-to-market
Men and couples seeking contraceptive options, plus clinical trial participants recruited through the company's website.
Geography
Headquartered at 818 E. Jefferson St., Suite 201, Charlottesville, Virginia, with a stated goal of serving men and couples worldwide.
Risks & controversies
Contraline's products are investigational and have not been approved by the FDA or any other regulatory authority, leaving development and approval outcomes unresolved.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
2 people who came through Contraline went on to found or lead other companies.
Competitors · 1
by search overlapCompanies competing with Contraline for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 2
launches, deals, and filingsContraline announced a $92.5 million Series B financing to advance its male contraception programs.
$92.5M source ↗
Contraline's website timeline states that two of its investigational male contraceptives completed clinical trials in 2025. Its products remain investigational and are not approved by the FDA or any other regulatory authority.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series Bfiercebiotech.com · Aug 2026
Contraline has filed a notice of an exempt offering of securities to raise $115,929,658.00 in New Funding. - intelligence360intelligence360.news · Jul 2026
Contraline Secures $92.5M to Push Its Male Birth Control Candidates Forward - MedCity Newsmedcitynews.com · Jun 2026
Contraline Closes $92.5M Series B for Male Contraceptiveallsci.com · Jun 2026▸Research sources · 1
primary sources listed
- Contralinecontraline.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Contraline do?
- Contraline is a clinical-stage company developing reversible male contraceptive products, including an implant and a topical gel.
- Who founded Contraline?
- Contraline was founded by Kevin Eisenfrats, John Herr in 2017.
- Who are Contraline's investors?
- Contraline's investors include Biotechnology Value Fund, MBX Capital, Allied Venture Partners, Amboy Street Ventures, Aurum Venture Partners, Beni Venture Capital, Cleo Capital, Evolution VC Partners and 13 more.
- How much funding has Contraline raised?
- Contraline has disclosed $155.5M raised across 3 of its 5 known rounds.
- Where is Contraline headquartered?
- Contraline is headquartered in Charlottesville, US.